Abstract
At present, antihypertensive treatment usually constitutes a preventive measure rather than a true therapeutic necessity. This is obviously due to the fact that arterial hypertension (AH) is one of the main risk factors for ischemic heart disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
World Health Organization: Arterial hypertension. Report of an expert committee. WHO Technical Report Series No 628,1978; 1–57.
Meier M, Orwin J, Rogg H, Brunner H: β-adrenoceptor antagonists in hypertension. In: Scriabine A (ed) Pharmacology of antihypertensive drugs. Raven Press, New York, 1980; 179–194.
Berglund G, Wilhelmsen L, Sannerstedt R, Hansson L, Andersson O, Sivertsson R, Wedel H, Wikstrand J: Coronary heart disease after treatment of hypertension. Lancet 1978; 1: 1–5.
Steward IMG: β-adrenoceptor blockade and the incidence of myocardial infarction during treatment of severe hypertension. Br Clin Pharmacol 1982; 13: 91–93.
Trafford JAP, Horn CR, O’Neal H, McGonigle R, Halford-Maw L, Evans R: Five years follow-up of effects of treatment of mild and moderate hypertension. Br Med J 1981; 282: 1111–1113.
Beevers DG, Johnston JG, Larkin H, Davies P: Clinical evidence that β-adrenoceptor blockers prevent more cardiovascular complications than other antihypertensive drugs. Drugs, 1983; 25 (Suppl 2): 326–330.
Scriabine A: β-adrenoceptor blocking drugs in hypertension. Ann Rev Pharmacol Toxicol 1979; 19: 269–284.
Opie LH: Drugs and the heart. I β-blocking agents. Lancet 1980; 1: 693–698.
Frishman WH: β-adrenoceptor antagonists: New drugs and new indications. N Engl J Med 1981; 305: 500–506.
Robertson JIS: State of the art review: β-blockade and the treatment of hypertension. Drugs, 1983; 25 (Suppl 2): 5–11.
Woods PB, Robinson ML: An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol 1981; 33: 172–173.
Johnson G, Regards CG: Clinical pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacol 1976; 1: 233–263.
Frishman W: Clinical pharmacology of the new β-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J 1979; 97: 663–670.
George GF: Pharmacodynamics and pharmacokinetics of cardiovascular drugs. In: Coltart J, Jewitt D (eds) Recent developments in cardiovascular drugs. Churchill Livingstone, Edinburgh, 1982; 16$27.
Shand DG: State of the art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs 1983; 25 (Suppl 2): 92–99.
Powel CE, Slater IH: Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther 1958; 122: 480–488.
Kaumann AJ: Herz β-Rezeptoren. Experimentelle Standpunkte. Z Kardiol 1983; 72: 63–82.
Langer SZ, Cavero I, Massingham B: Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980; 2: 373–382.
Tackett RL, Webb IG, Privitera PJ: Cerebroventricular propanolol elevates cerebrospinal fluid norepinephrine and lowers arterial pressure. Science 1981; 213: 911–913.
Cruickshank JM: How safe are the β-blockers? Drugs 1983; 25 (Suppl 2): 331–340.
Breckenridge A: Which β-blocker? Br Med J 1983; 286: 1085–1088.
Gallery EDM, Saunders DM, Hunyor SN, Gyory AZ: Randomized comparison of methyldopa and oxprenolol for treatment of hypertension in pregnancy. Br Med J 1979; 1: 1591–1594.
Rubin PC, Butters L, Clark DM et al.: Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet 1983; 1: 431–434.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Ezquerra, E.A., Arrieta, J.A., Huguet, R., Barba, J., Martinez-Caro, D. (1988). Use of β-Adrenergic Blocking Agents in Arterial Hypertension. In: de Luna, A.B., Betriu, A., Permanyer, G. (eds) Therapeutics in Cardiology. Developments in Cardiovascular Medicine, vol 81. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1333-2_27
Download citation
DOI: https://doi.org/10.1007/978-94-009-1333-2_27
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7094-2
Online ISBN: 978-94-009-1333-2
eBook Packages: Springer Book Archive